CSI Market
Sign In | Register

Biolife Solutions Inc (BLFS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BLFS quarterly Cash Flow →
A period-by-period view of cash flow from Biolife Solutions Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-4.60
Depreciation & amortization2.25
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.27
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets-10.31
Share-based Compensation22.99
Noncash Contribution Expense5.30
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Accrued Interest Related Parties-
Deconsolidation Gain Or Loss Amount-
Write Off Of Deferred Debt Issuance Cost-
Writeoff Of Deferred Financing Costs-
Amortization Of Deferred Rent-
Amortization Of Operating Lease Liability-
Noncash Lease Expense-
Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss-
Gain Loss On Disposition Of Assets Held For Rent0.51
Gain Loss On Acquisition Of Business-
Increase Decrease In Warranty Liability-
Increase Decrease In Warranty Liability-
Increase Decrease In Warranty Liability-
Increase Decrease In Warranty Liability-
Intangible Asset Impairment-
Increase Decrease In Equity Securities Fv Ni-0.98
Payments For Settlement Escrow-
Warranty Liability0.01
Amortization Of Intangible Assets Consolidated Basis2.43
Debt Securities Available For Sale Unrealized Gain Loss0.11
Increase Decrease In Prepaid Expense Other Current Assets And Long Term Deposits-3.04
Income taxes-1.84
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.26
Increase (Decrease) in Accounts Payable-2.09
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-1.14
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.26
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities11.25
Discontinued operations0.00
Net Cash flow from Operating Activities20.12
Investing Activities
Capital Expenditures-9.48
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt6.83
Payments to Acquire Available-for-sale Securities, Debt-114.06
Real Estate Investments0.00
Payments To Acquire Assets Held For Rent-0.89
Payments To Acquire Investments In Non Marketable Equity Securities And Available For Sale Debt Securities-
Business Combination Consideration Transferred Equity Interests Issued And Issuable-
Business Combination Consideration Transferred Equity Interests Issued And Issuable-
Business Combination Consideration Transferred Equity Interests Issued And Issuable-
Business Combination Consideration Transferred Equity Interests Issued And Issuable-
Business Combination Consideration Transferred Equity Interests Issued And Issuable-
Payments From Divestiture Of Businesses-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-10.22
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses23.52
Accounts payable0.00
Payments to Acquire Notes Receivable-2.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net34.76
Discontinued operations0.00
Net Cash Flow from Investing Activities-71.54
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-10.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.03
Proceeds From Exercise Of Common Stock Options And Warrants-
Payments On Equipment Financing-
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Reclassification Of Property And Equipment To Assets Held For Rent-
Reclassification Of Warrant Liabilities To Equity Upon Exercise-
Capital Expenditures Incurred But Not Yet Paid-
Stock Issued-
Registration Filings Fees-
Proceeds From Repayments Of Financed Insurance Premium-
Proceeds From Financed Insurance Premium-
Repayments Of Financed Insurance Premium-0.98
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-10.92
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow10.64
Total Cash Flow-62.35
4 historic quarters locked

Sign in to unlock the full Biolife Solutions Inc cash flow history.

Sign In Create Free Account

About Biolife Solutions Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: blfs-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-012294

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document